135 related articles for article (PubMed ID: 1954991)
1. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma.
Boccadoro M; Battaglio S; Omedè P; Palumbo AP; Fusaro A; Frieri R; Gallone G; Polloni R; Mosso R; De Filippi PG
Eur J Haematol; 1991 Oct; 47(4):305-9. PubMed ID: 1954991
[TBL] [Abstract][Full Text] [Related]
2. Serum neopterin and beta 2-microglobulin concentrations in monoclonal gammopathies.
Fine JM; Lambin P; Desjobert H
Acta Med Scand; 1988; 224(2):179-82. PubMed ID: 3048055
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
Nachbaur DM; Herold M; Maneschg A; Huber H
Ann Hematol; 1991; 62(2-3):54-8. PubMed ID: 2031968
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: an immunoclinical study of disease and response to treatment.
Thavasu PW; Ganjoo RK; Maidment SA; Love SB; Williams AH; Malplas JS; Balkwill FR
Hematol Oncol; 1995; 13(2):69-82. PubMed ID: 7797195
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
7. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for multiple myeloma.
Reibnegger G; Fuchs D; Wachter H
Blood; 1994 Aug; 84(4):1350-1. PubMed ID: 8049453
[No Abstract] [Full Text] [Related]
9. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.
Bartl R; Frisch B; Diem H; Mündel M; Nagel D; Lamerz R; Fateh-Moghadam A
Cancer; 1991 Nov; 68(10):2241-50. PubMed ID: 1913461
[TBL] [Abstract][Full Text] [Related]
10. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
11. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
12. Relationship and prognostic value of endogenous interferon-alpha, beta 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS.
Krown SE; Niedzwiecki D; Bhalla RB; Flomenberg N; Bundow D; Chapman D
J Acquir Immune Defic Syndr (1988); 1991; 4(9):871-80. PubMed ID: 1895208
[TBL] [Abstract][Full Text] [Related]
13. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population.
Diamondstone LS; Tollerud DJ; Fuchs D; Wachter H; Brown LM; Maloney E; Kurman CC; Nelson DL; Blattner WA
J Clin Immunol; 1994 Nov; 14(6):368-74. PubMed ID: 7883864
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
Reibnegger G; Krainer M; Herold M; Ludwig H; Wachter H; Huber H
Cancer Res; 1991 Dec; 51(23 Pt 1):6250-3. PubMed ID: 1933885
[TBL] [Abstract][Full Text] [Related]
16. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
18. Serum beta 2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: a clinical study of 55 patients.
Chelazzi G; Senaldi G
Ric Clin Lab; 1986; 16(1):53-8. PubMed ID: 3090677
[TBL] [Abstract][Full Text] [Related]
19. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
[TBL] [Abstract][Full Text] [Related]
20. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
